Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(80.0%)

Phase 3

1(20.0%)

5Total

Phase 2(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02697136Phase 3Terminated

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

Role: lead

NCT02484378Phase 2Completed

CER-001 Atherosclerosis Regression ACS Trial

Role: lead

NCT01412034Phase 2Completed

Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects

Role: lead

NCT01201837Phase 2Completed

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

Role: lead

NCT01515241Phase 2Completed

Exploratory Study of Plaque Regression

Role: lead

All 5 trials loaded